# Blue Water Life Science Fund

> Blue Water Life Science Fund is a VC fund in Mill Valley backing Biotechnology and Medical. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Mill Valley, United States
- Total investments: 5
- Last investment: May 2024
- Lead investor: 0%
- Last updated: Aug 2026

Blue Water Life Science Fund is a VC fund in Mill Valley focused on Biotechnology and Medical. Blue Water Life Science Fund

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Medical | 2 | 40% |
| Genetics | 2 | 40% |
| Health Care | 2 | 40% |
| Pharmaceutical | 2 | 40% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 40% |
| Post-IPO Equity | 2 | 40% |
| Series E | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Karius | Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a majorthreat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing. | $100M | Series C | May 02, 2024 |  |
| Visby Medical | Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools thatare both highly accurate and delightful to use. | $100M | Series E | Mar 01, 2022 |  |
| Pear Therapeutics | Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients toget better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors. | $125M | Post-IPO Equity | Dec 06, 2021 |  |
| NeoGenomics | NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States,and pharmaceutical firms in Europe and Asia. | $200M | Post-IPO Equity | May 05, 2021 |  |
| Pear Therapeutics | Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients toget better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors. | $64M | Series C | Jan 04, 2019 |  |

5 of 5 investments shown.

## Co-investors
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 3 deals together
- [Arboretum Ventures](https://shizune.co/investors/profile/arboretum-ventures) — VC Fund, 2 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 2 deals together
- [Jazz Venture Partners](https://shizune.co/investors/profile/jazz-venture-partners) — VC Fund, 2 deals together
- [SoftBank Vision Fund](https://shizune.co/investors/profile/softbank-vision-fund) — VC Fund, 2 deals together
- [Temasek](https://shizune.co/investors/profile/temasek) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Blue Water Life Science Fund invest in?

Blue Water Life Science Fund invests primarily in Biotechnology, Medical and Genetics startups, most often at Series C and Post-IPO Equity stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Blue Water Life Science Fund last invest?

The most recent investment recorded for Blue Water Life Science Fund closed in May 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co